Healthcare resource utilization after initiation of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors or other glucose‐lowering drugs in Japanese patients with type 2 diabetes

SGLT-2 inhibitors are associated with a lower overall mean cumulative cost per patient by $2545 compared to DPP-4 inhibitors and by $2330 compared to other glucose-lowering drugs after 2.5 years.

• Patients initiated on SGLT-2 inhibitors had higher diabetes medication costs than those on DPP-4 inhibitors or other glucose-lowering drugs.
• SGLT-2 inhibitors were associated with a lower frequency of hospitalizations.
• Patients on SGLT-2 inhibitors experienced a shorter total hospital stay by 213.0 days per 100 patient-years compared to DPP-4 inhibitors and by 204.6 days compared to other glucose-lowering drugs.
• Healthcare resource utilization was examined in 228,514 type 2 diabetes patients using a nationwide database from Japan.
• Baseline characteristics, including healthcare costs, were well balanced after propensity score matching.

AI simplified